Nasdaq apls.

3 дня назад ... The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Tags.The APLS shares have gain 13.10% over the last week, with a monthly amount glided 10.71%, and seem to be holding up well over. A share price of Apellis Pharmaceuticals Inc [APLS] is currently trading at $53.87, up 7.10%. An important factor to consider is whether the stock is rising or falling in short-term value. The APLS shares …Headline. APLS Jan 2025 120.000 put. finance.yahoo.com - November 23 at 9:19 AM. Apellis Pharmaceuticals (NASDAQ:APLS) Trading Down 3.7% After Insider Selling. americanbankingnews.com - November 23 at 1:49 AM. Alec Machiels Sells 1,250 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock. americanbankingnews.com - November 22 at 4:44 AM.Stock Quote. NASDAQ: APLS. $61.58. Dec 1, 2023 4:00 PM EST. Change+7.71 (0.00%); Volume5,431,264; Today's Open$53.99; Previous Close$61.58. Today's High$61.69 ...Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Novartis Announces FDA Approval Of Prostat...

WALTHAM, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the ...

May 18, 2023 · deliormanli. Background. Apellis Pharmaceuticals (NASDAQ:APLS), is a US-based commercial biotech focused on innovative biologics that inhibit the complement system via C3 targeting.The firm's ... Apellis Pharmaceuticals, Inc. APLS reported a loss per share of $1.50 for fourth-quarter 2022, narrower than the Zacks Consensus Estimate of a loss of $1.65. The loss was also narrower than our ...

Nov 1, 2023 · The firm increased its portfolio allocation in APLS by 653.58% over the last quarter. VGHCX - Vanguard Health Care Fund Investor Shares holds 5,895K shares representing 5.01% ownership of the company. Analyst's Opinion · Consensus Rating. Apellis Pharmaceuticals has received a consensus rating of Moderate Buy. · Price Target Upside/Downside. According to ...The public float for APLS is 96.80M and currently, short sellers hold a 16.67% of that float. On November 29, 2023, APLS’s average trading volume was 2.29M shares. APLS) stock’s latest price update. Apellis Pharmaceuticals Inc (NASDAQ: APLS)’s stock price has plunge by 5.56relation to previous closing price of 47.16.Apellis Pharmaceuticals (APLS) Stock Forecast and Price Target 2023 Free Trial Top-Rated Stocks Most-Upgraded Stocks Apellis Pharmaceuticals (APLS) Stock …Apellis Pharmaceuticals, Inc. Common Stock (APLS) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets.

May 14, 2021 · WALTHAM, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the U.S ...

9 de set. de 2023 ... Fintel reports that on September 8, 2023, B of A Securities maintained coverage of Apellis Pharmaceuticals (NASDAQ:APLS) with a Neutral ...

... Pharmaceuticals (NASDAQ: APLS). Wedbush Analyst forecast on APLS. Laura ChicoWedbush. 08/29/23. $29.00. Hold. -40.94%. Downside. Reiterated. Follow. 0. 0.Oct 20, 2023 · WALTHAM, Mass., Oct. 20, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that The Lancet published the positive 24-month results from the Phase 3 OAKS and ... WALTHAM, Mass., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced that the ...Nov 1, 2023 · The firm increased its portfolio allocation in APLS by 653.58% over the last quarter. VGHCX - Vanguard Health Care Fund Investor Shares holds 5,895K shares representing 5.01% ownership of the company. 31 de jul. de 2023 ... On today's stock market, APLS stock plummeted 19.6% to close at 25.75. ... *Real-time prices by Nasdaq Last Sale. Realtime quote and/or trade ...Follow. WALTHAM, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that four oral ...Nov 30, 2023 · Apellis Pharmaceuticals (NASDAQ:APLS) and Intra-Cellular Therapies (NASDAQ:ITCI) are both mid-cap medical companies, but which is the better stock?We will compare the two companies based on the strength of their risk, analyst recommendations, community ranking, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.

Find the latest Institutional Holdings data for Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com. Nov 30, 2023 · Apellis Pharmaceuticals (NASDAQ:APLS) and Intra-Cellular Therapies (NASDAQ:ITCI) are both mid-cap medical companies, but which is the better stock?We will compare the two companies based on the strength of their risk, analyst recommendations, community ranking, institutional ownership, media sentiment, valuation, dividends, earnings and profitability. Reported EPS is $-1.17 EPS, expectations were $-0.86. Operator: Good morning ladies and gentlemen. Thank you for standing by and welcome to the Apellis Pharmaceuticals Third Quarter 2023 Earnings ...Nov 2, 2023 · Apellis Pharmaceuticals, Inc. APLS reported third-quarter 2023 loss of $1.17 per share, which was wider than the Zacks Consensus Estimate of a loss of 84 cents. The company had reported a loss of ... WALTHAM, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will present at the 2021 Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 8:40 a.m. ET. The conference will be …Dec 1, 2023 · How much insider selling is happening at Apellis Pharmaceuticals? Insiders have sold a total of 851,250 Apellis Pharmaceuticals shares in the last 24 months for a total of $50,097,256.67 sold. Apellis Pharmaceuticals (NASDAQ: APLS) · Apellis Pharmaceuticals Return vs. S&P · Apellis Pharmaceuticals Company Info · News & Analysis · Financial Health ...

Funds + ETFs. After-Hours Quotes. See All Market Activity->. News + Insights.Apellis Pharmaceuticals, Inc. APLS reported third-quarter 2023 loss of $1.17 per share, which was wider than the Zacks Consensus Estimate of a loss of 84 cents. The company had reported a loss of ...

WALTHAM, Mass., March 16, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced longer-term data from ...As of Q1 2023, Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) was the most commonly held stock out of the 12 stocks with biggest upside potential according to analysts. Its shares were held by 42 of ...May 4, 2023 · Operating as a commercial-stage biopharmaceutical entity, Apellis Pharmaceuticals (NASDAQ:APLS) is dedicated to the discovery, development, and market introduction of groundbreaking therapeutic ... The crowded complement inhibitor field will be watching closely FDA’s decision, due Nov. 26, on C3 inhibitor pegcetacoplan from Apellis Pharmaceuticals Inc. (NASDAQ:APLS). The therapy is one of six complement inhibitors in development for the indication, with the next in line, Zimura avacincaptad pegol from Iveric bio Inc. …NASDAQ:APLS Long Term Investor Notice: Investigation of Potential Wrongdoing at Apellis Pharmaceuticals, Inc. An investigation on behalf of current long term investors in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) shares over possible breaches of fiduciary duty by certain officers and directors was announced.Follow. WALTHAM, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced the pricing of ...The average twelve-month price prediction for Apellis Pharmaceuticals is $66.50 with a high price target of $93.00 and a low price target of $29.00. Learn more on APLS's analyst rating history. Do Wall Street analysts like Apellis Pharmaceuticals more than its competitors?

Apellis Pharmaceuticals, Inc. APLS reported a loss per share of $1.50 for fourth-quarter 2022, narrower than the Zacks Consensus Estimate of a loss of $1.65. The loss was also narrower than our ...

Apellis Pharmaceuticals Stock Down 1.9 %. Shares of NASDAQ:APLS opened at $60.40 on Monday. The company’s fifty day moving average price is $46.23 and its 200 day moving average price is $55.22.

Aug 31, 2023 · Fintel reports that on September 15, 2023, Wells Fargo upgraded their outlook for Apellis Pharmaceuticals (NASDAQ:APLS) from Equal-Weight to Overweight.. Analyst Price Forecast Suggests 53.76% ... How much insider selling is happening at Apellis Pharmaceuticals? Insiders have sold a total of 851,250 Apellis Pharmaceuticals shares in the last 24 months for a total of $50,097,256.67 sold.Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is a commercial-stage biopharmaceutical company that specializes in discovering, developing, and selling therapeutic compounds that work by inhibiting ...Apellis Pharmaceuticals, Inc. APLS reported a loss per share of $1.50 for fourth-quarter 2022, narrower than the Zacks Consensus Estimate of a loss of $1.65. The loss was also narrower than our ...On this news, shares of Apellis fell $6.27 per share, or approximately 19.6%, from a close of $32.02 per share on July 28, 2023, to close at $25.75 per share on July 31, 2023. The case is ...Dec 1, 2023 · The average twelve-month price prediction for Apellis Pharmaceuticals is $66.50 with a high price target of $93.00 and a low price target of $29.00. Learn more on APLS's analyst rating history. Do Wall Street analysts like Apellis Pharmaceuticals more than its competitors? As of Q1 2023, Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) was the most commonly held stock out of the 12 stocks with biggest upside potential according to analysts. Its shares were held by 42 of ...WALTHAM, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will ...Apellis Pharmaceuticals (NASDAQ:APLS) raised ~$150m via its initial public offering ("IPO") back in November 2017, issuing just over 10.7m share at a price of $14 per share. The company described ...

CRESTWOOD, Ky., and WALTHAM Mass., June 26, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel ...WALTHAM, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will ...WALTHAM Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company ...WALTHAM, Mass., March 16, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced longer-term data from ...Instagram:https://instagram. arm valuationp.g.r.best dental insurance for dentures no waiting periodhow to switch health insurance companies 14 de dez. de 2017 ... Apellis Pharmaceuticals, Inc. [$APLS] rings the closing bell! sdybuy russian rubles 14 нояб. 2023 г. ... Is Apellis Pharmaceuticals (NASDAQ:APLS) a buy? Compare the latest price, visualised quantitative ratios, annual reports, ...View today's Apellis Pharmaceuticals Inc stock price and latest APLS news and analysis. Create real-time notifications to follow any changes in the live ... russell 2000 index chart The chart below shows the one year performance of APLS shares: Looking at the chart above, APLS's low point in its 52 week range is $42.15 per share, with $94.75 as the 52 week high point — that ...Nov 22, 2023 · Apellis Pharmaceuticals Inc (NASDAQ: APLS)’s stock price has dropped by -3.62 in relation to previous closing price of 49.36. Nevertheless, the company has seen a loss of -1.71% in its stock price over the last five trading days. Zacks Investment Research reported 2023-11-09 that FATE reports better-than-expected third-quarter 2023 financial results, driven by lower operating […]